# ZLAB earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/ZLAB) · [Earnings tab](https://www.lopjlb.com/stock/ZLAB?tab=earnings)

Updated: 2026-08-06T06:04:54

Quarters analyzed: 8

## Cross-quarter narrative

Across the earnings calls, Zai Lab's revenue growth has been driven by the strong launch of VYVGART, with the company raising its guidance for the product. The pipeline has advanced, with multiple assets in various stages of development, including ZL-1310, KarXT, and bemarituzumab. Despite facing regulatory, commercial, and competitive risks, the company has reaffirmed its revenue guidance and targets profitability by the end of 2025. However, supply constraints have limited the growth of XACDURO, and the company faces uncertainty in its guidance for 2026 due to macro headwinds and pricing adjustments.

## Latest CallCard · Q1

Zai Lab Q1 2026: revenue fell 6% YoY to $99.6M on ZEJULA pressure; VYVGART volume grew double-digits but price cut 12%; XACDURO demand strong but supply constrained. Zoci Phase III DLLEVATE enrolling well, on track for H1 2027 enrollment completion, BLA submission late 2027. Amgen/BI collaborations 

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2026 Q1:** Zai Lab Q1 2026: revenue fell 6% YoY to $99.6M on ZEJULA pressure; VYVGART volume grew double-digits but price cut 12%; XACDURO demand strong but supply constrained. Zoci Phase III DLLEVATE enrolling well, on track for H1 2027 enrollment completion, BLA submission late 2027. Amgen/BI collaborations 
- **2025 Q4:** Zai Lab reports 15% YoY revenue growth, improving profitability, and rapid advancement of its global oncology pipeline, while noting macro headwinds and guidance uncertainty for 2026.
- **2025 Q3:** Zai Lab reports profitable China business, strong pipeline progress with Zoci advancing to Phase III and new assets entering early‑stage trials, while VYVGART growth is slower than expected and supply constraints linger.
- **2025 Q2:** Zai Lab reaffirmed 2025 revenue guidance of $560‑590M, expects adjusted profitability in Q4, cites strong VYVGART momentum and multiple pipeline milestones including ZL‑1310, bemarituzumab and TTFields.
- **2025 Q1:** Zai Lab reaffirms $560-590M FY25 revenue guidance, targets Q4 profitability, advances global pipeline (ZL-1310 ASCO data, pivotal 2027), prepares KarXT/bemarituzumab/TTFields launches. VYVGART demand rebounding post-CNY; XACDURO strong start; NRDL and FDA uncertainties remain. Operating loss improve
- **2024 Q4:** Zai Lab posted 50% revenue growth in 2024, highlighted strong VYVGART launch and advancing pipeline assets like ZL-1310, while guiding 2025 revenue to $560‑$590M and targeting profitability in Q4 2025.
- **2024 Q3:** Zai Lab reports 47% Q3 revenue growth, strong VYVGART launch momentum, advancing pipeline assets like ZL-1310 and KarXT, and aims for profitability by end‑2025.
- **2024 Q2:** Zai Lab Q2 net product revenue $100.1M (+45% YoY), driven by VYVGART launch; raised VYVGART FY guidance to >$80M; three approvals; pipeline advancing; $730M cash; targeting profitability by end-2025.','tone': {'mgmt': 0.8, 'mgmt_rationale': 'Management highlighted strong revenue growth, raised guida

## Theme arcs

- **Revenue Growth** (improving): Driven by VYVGART launch
- **Pipeline Advancement** (improving): Multiple assets in development
- **Regulatory Risks** (deteriorating): Uncertainty in approval timelines
- **Commercial Risks** (deteriorating): Supply constraints and competition
- **Guidance Uncertainty** (deteriorating): Macro headwinds and pricing adjustments

## Fear persistence

- **Regulatory Risk** [recurring]: Uncertainty in approval timelines
- **Commercial Risk** [recurring]: Supply constraints and competition
- **Guidance Uncertainty** [recurring]: Macro headwinds and pricing adjustments
- **Clinical Trial Risk** [recurring]: Uncertainty in achieving efficacy endpoints
- **Competitive Risk** [recurring]: Generic competition and emerging therapies

## Guidance path

2024 Q2:vague → 2024 Q3:maintained → 2024 Q4:maintained → 2025 Q1:vague → 2025 Q2:maintained → 2025 Q3:raised → 2025 Q4:vague → 2026 Q1:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/ZLAB`